ArticleInternational journal of cardiology. Heart & vasculature2026
Retrospective evaluation of Selexipag monotherapy on pulmonary hemodynamics in newly diagnosed, treatment-naïve patients with chronic thromboembolic pulmonary hypertension prior to balloon pulmonary angioplasty.
Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Selexipag has been approved for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) in Japan since April 2021; however, its hemodynamic effects in treatment-naïve patients with inoperable CTEPH prior to balloon pulmonary angioplasty (BPA) remain unclear. This study evaluated the impact of selexipag monotherapy on pulmonary hemodynamics before first BPA. Methods: Between August 2021 and February 2024, 40 newly diagnosed, treatment-naïve patients with inoperable CTEPH undergoing their initial BPA session were screened at Yokohama City University Hospital. After excluding three patients in the riociguat group due to insufficient titration time, 30 patients (15 selexipag, 15 riociguat) were included in this retrospective observational study. Hemodynamic parameters were assessed before and after pharmacotherapy and compared within and between groups. Results: The selexipag group included 10 women (mean age 66.5 years; average dose 2.2 mg/day). Selexipag significantly reduced mean pulmonary arterial pressure (mPAP) from 39.0 to 33.6 mmHg (-5.4 ± 6.7 mmHg; Conclusions: In this exploratory, hypothesis-generating retrospective study, selexipag monotherapy was associated with reductions in mPAP and PVR in treatment-naïve patients with inoperable CTEPH before BPA, whereas riociguat showed greater CO improvement. These findings warrant prospective validation in selected patients before broader clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.